EW EDWARDS LIFESCIENCES CORP

Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024

IRVINE, Calif.--(BUSINESS WIRE)--

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at .

About Edwards Lifesciences

Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

EN
30/01/2024

Underlying

EWEDWARDS LIFESCIENCES CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EDWARDS LIFESCIENCES CORP

Free Trial
EW EDWARDS LIFESCI...

Edwards Lifesciences Corp: 1 director

A director at Edwards Lifesciences Corp sold 25,000 shares at 65.915USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

EW EDWARDS LIFESCIENCES CORP
11/06/24 November 6, 2024 1 EN
 PRESS RELEASE
Free
EW EDWARDS LIFESCI...

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enro...

October 24, 2024 1 EN
 PRESS RELEASE
Free
EW EDWARDS LIFESCI...

Edwards Lifesciences to Host Earnings Conference Call on October 24, 2...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart...

October 17, 2024 1 EN
EUR 239.98
EW EDWARDS LIFESCI...

Edwards Lifesciences Corporation: Update to credit analysis following ...

Our credit view of this issuer reflects its conservative financial policies including very low leverage, against its very high concentration in one product segment.

EW EDWARDS LIFESCIENCES CORP
09/17/24 September 17, 2024 1 EN
EUR 172.78
EW EDWARDS LIFESCI...

Moody's Ratings affirms Edwards Lifesciences' Baa2 ratings

Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. The outlook is stable. The rating affirmation reflects our view that Edwards will continue to sustain leadership an...

EW EDWARDS LIFESCIENCES CORP
09/16/24 September 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch